Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
Xie, Shitong ; Sheng, Yanan ; Chuang, Ling-Hsiang ; Wu, Jing
Health economics review, 2024-12, Vol.14 (1), p.38-10 [Periódico revisado por pares]Berlin/Heidelberg: Springer Berlin Heidelberg
Texto completo disponível